Anupam Rasayan India Limited has submitted to the Exchange, the financial results for the quarter and financial year ended March 31, 2026.
ANURAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anupam Rasayan India Limited reported strong FY26 results with standalone revenue of Rs 16,755.67 million (up 87% YoY) and consolidated revenue of Rs 23,654.55 million (up 65% YoY). Standalone PAT grew 122% to Rs 1,613.96 million while consolidated PAT rose 39% to Rs 2,221.99 million. The Board recommended a final dividend of Rs 1.5 per share (15% of face value). Key corporate actions include planned acquisition of Bliss GVS Pharma Limited (up to 74.20% stake), issuance of Rs 160 crore NCDs on private placement basis, and resignation of Deputy CFO Mr. Vishal Thakkar. The company also completed acquisition of US-based Jayhawk Fine Chemicals Corporation (part of CABB group) for USD 150 million. Auditors issued unmodified opinion (clean audit).
Strong financial performance with near-doubling of standalone profit. The large NCD issuance and planned acquisition indicate aggressive expansion plans which may increase leverage. Positive dividend signals management confidence.